PIM
PACB icon

Platinum Investment Management’s Pacific Biosciences PACB Stock Holding History

Platinum Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-261,242
Closed -$6.67M – 151
2021
Q3 		$6.67M Hold
261,242
– – 0.19% 54
2021
Q2 		$9.14M Hold
261,242
– – 0.21% 47
2021
Q1 		$8.7M Sell
261,242
-179,018
-41% -$6.27M 0.19% 43
2020
Q4 		$11.4M Sell
440,260
-257,653
-37% -$4.38M 0.26% 44
2020
Q3 		$6.89M Sell
697,913
-158,613
-19% -$913K 0.17% 49
2020
Q2 		$2.96M Buy
856,526
+356,830
+71% +$1.21M 0.07% 69
2020
Q1 		$1.53M Buy
499,696
+252,221
+102% +$1.03M 0.04% 82
2019
Q4 		$1.27M Buy
+247,475
New +$1.26M 0.03% 78

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Platinum Investment Management's PACB Position: Q4 2021 in Review

Platinum Investment Management sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 261,242 shares — an estimated $6.67M sold.

Platinum Investment Management first reported a position in PACB in Q4 2019 and held it in 8 quarters. The position peaked at $11.4M in Q4 2020. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

  • Platinum Investment Management reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
  • Platinum Investment Management sold 261,242 Pacific Biosciences shares in Q4 2021, an estimated $6.67M.
  • Platinum Investment Management first reported a position in Pacific Biosciences in Q4 2019 and held it in 8 quarters.
  • Platinum Investment Management's Pacific Biosciences position peaked at $11.4M in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on Platinum Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.